"We were surprised to see
that even within the same company, they had such a remarkable diversity in
terms of biosimilar market share, in terms of the prices they were paying, and
how much biosimilars they were able to use."
— Mariana Socal, a physician and researcher at the Johns Hopkins
Bloomberg School of Public Health, spoke with AIS's RADAR on Drug Benefits about her latest
research on biosimilar use in the U.S. The study concluded that market and
regulatory barriers are preventing biosimilars from realizing their full
savings potential for insurers.
No comments:
Post a Comment